Jubilant Ingrevia Limited reported its financial results for the third quarter (Q3) and nine months (9M) ended December 31, 2024. The company’s total revenue in Q3 FY25 stood at ₹1,056.77 crore, marking a 9.4% year-on-year (YoY) increase from ₹966.40 crore in Q3 FY24. On a quarter-on-quarter (QoQ) basis, revenue showed a marginal growth of 1.1% compared to ₹1,045.24 crore in Q2 FY25.
The company reported a significant increase in net profit, which rose 73.6% YoY to ₹95.57 crore in Q3 FY25, up from ₹55.05 crore in Q3 FY24. The sequential increase in profit was 18.9% from ₹80.36 crore in Q2 FY25.
Operational highlights:
- Total EBITDA stood at ₹148 crore in Q3 FY25, reflecting a 41.5% YoY growth from ₹104 crore in Q3 FY24 and a 9.4% QoQ rise from ₹135 crore in Q2 FY25.
- EBITDA margin improved to 14%, up from 11% YoY and stable sequentially from 13% in Q2 FY25.
- Profit after tax (PAT) margin increased to 7% from 4% in Q3 FY24 and 6% in Q2 FY25.
- Basic and diluted EPS stood at ₹4.4 in Q3 FY25, an 80% YoY jump from ₹2.4 in Q3 FY24.
9M FY25 performance:
For the nine months ended December 31, 2024, Jubilant Ingrevia recorded total revenue of ₹3,126 crore, reflecting a 2.1% YoY growth compared to ₹3,061 crore in 9M FY24. Net profit for 9M FY25 stood at ₹177 crore, up 15.3% YoY from ₹154 crore in 9M FY24. EBITDA for the nine-month period rose 12.9% YoY to ₹402 crore.
Dividend announcement:
The company’s Board has recommended an interim dividend of 250% (₹2.5 per equity share of face value ₹1 each) for FY25, amounting to a total payout of ₹39.8 crore.
Market trends:
- Chemicals Markets showed gradual volume improvements, though pricing remained muted across segments.
- Pharmaceutical End-Use Market maintained steady demand, with stable pricing and volumes.
- Agrochemical Sector continued its positive momentum, with YoY and QoQ growth in volumes.
- Nutrition Market saw increased demand, particularly in choline products, though niacinamide prices remained stable.
Jubilant Ingrevia remains focused on enhancing operational efficiencies and driving cost optimization initiatives. The company expects continued growth momentum across its key business segments, supported by strategic expansions and improved operational performance.